The purpose of this document is to provide relevant information and guidelines on
coronavirus outbreaks – and in particular the novel coronavirus SARS-CoV-2 and the
diseases it produces, COVID-19 – for pharmacists and the pharmacy workforce, both in a
primary care context (i.e. community phar...macies and primary healthcare facilities) and in
hospital settings, as well as for pharmacists working as clinical biologists in medical
analysis laboratories, for example, as clinical biologists, and offer a set of references that
may be consulted for more informationstor
more
Blueprint for EECA countries, first edition
МОДЕЛЬ ПРОТИВОТУБЕРКУЛЕЗНОЙ ПОМОЩИ, ОРИЕНТИРОВАННАЯ НА НУЖДЫ ЛЮДЕЙ
Концептуальный проект модели для стран Восточной Европы и Центрально...й Азии, первое издание
more
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Усиление мер реагированиясистем здравоохранения на COVID-19: техническое руководство No 5: адаптация первичной медико-санитарной помощи для повышения эффективности о...ветных мер в связи с COVID-19 (17 июня 2020 г.)
Strengthening the health systems response to COVID-19: technical guidance
more
This plan, approved by the Organization’s 62nd Directing Council, was shaped by extensive consultations with countries and stakeholders, and commits to transformative health outcomes over the next six years, tackling noncommunicable diseases (NCDs), mental health, health security, fragmented healt...h systems and services, and the elimination of communicable diseases, amongst others.
“The COVID-19 pandemic taught us that the Region of the Americas is stronger when we work together,” said Dr. Jarbas Barbosa, PAHO Director. “This Strategic Plan harnesses our collective strength to build resilient health systems, reduce disease burden, and improve health and well-being for all across the Americas.”
The plan builds on lessons from the COVID-19 pandemic, which exposed gaps in health systems while highlighting the power of joint action. It targets measurable impacts in countries, such as reducing maternal mortality, reversing rising suicide rates, and eliminating diseases like leprosy and Chagas.
more
Guidance issued as of 25 March 2020
This guidance is intended for use by health authorities to guide the actions taken by health-care providers for refugees and migrants in relation to the novel coronavirus (COVID-19) outbreak. This document is intended to address the needs and rights of refugees a...nd migrants living in all types of setting.
General recommendations made by WHO in the COVID-19 response (link here) are the superseding guidelines. Unfounded measures regarding testing, health screening and quarantine should not be imposed on refugees and migrants.
more
Community Health Impact Coalition members & colleagues from across the world are sharing COVID-19 explainers, internal policies, clinical protocols, & more live
This WHO laboratory manual provides the most up to date methods and procedures for the laboratory identification of yellow fever virus infection in humans. It provides guidance on the establishment and maintenance of an effective laboratory providing routine surveillance testing for yellow fever, wh...ich operates within the WHO coordinated Global Yellow Fever Laboratory Network (GYFLaN) capable of providing confirmation of yellow fever infection reliably and timely. This second edition supersedes the first edition of the 2004 WHO manual for the monitoring of yellow fever virus infection.
more
Policy Brief. More languages available here https://apps.who.int/iris/handle/10665/179517
The WHO laboratory biosecurity guidance follows and complements the revision of the Laboratory biosafety manual, fourth edition and provides principles and measures to prevent lapses and incidents throughout the whole value chain of handling high-consequence biological material, technology and infor...mation. The document shares global best practice and covers the biosecurity part of the biological risk management lifecycle, starting from collection, transportation, storage and experiment, and in specific context such as every type of biomedical laboratory, research activities, repository and biobank. It also provides key considerations and best practices for institutional, national and international levels, including regulatory oversight.
more
Antimicrobials are medicines, including antibiotics, antivirals, antifungals, and antiparasitics, that are used to prevent and treat infections in humans, animals, and plants. Antimicrobial Resistance (AMR) arises when bacteria, viruses, fungi, and parasites no longer respond to these medicines, ren...dering them ineffective and making infections more difficult to treat. This resistance increases the risk of disease spread, severe illness, disability, and death. Although AMR is a natural phenomenon driven by genetic
changes in pathogens, it is significantly accelerated by human activities such as the misuse and overuse of antimicrobials in healthcare, agriculture, and animal husbandry.
more
The Global Schistosomiasis Alliance Diagnostic Workstream has developed a communications piece listing all commercially available diagnostics for schistosomiasis
Schistosomiasis is a helminthic infection and one of the neglected tropical diseases (NTDs). It is caused by blood flukes of the genus Schistosoma. It is an important public health problem, particularly in poverty-stricken areas, especially those within the tropics and subtropics. It is estimated th...at at least 236 million people worldwide are infected, 90% of them in sub-Saharan Africa, and that this disease causes approximately 300,000 deaths annually. The clinical manifestations are varied and affect practically all organs. There are substantial differences in the clinical presentation, depending on the phase and clinical form of schistosomiasis in which it occurs. Schistosomiasis can remain undiagnosed for a long period of time, with secondary clinical lesion. Here, we review the clinical profile of schistosomiasis. This information may aid in the development of more efficacious treatments and improved disease prognosis.
more